According to Zacks, “Nanobiotix S.A. is a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer. The company’s proprietary technology includes NBTXR3. Nanobiotix S.A. is headquartered in Paris, France. “
NBTX opened at $11.83 on Wednesday. The business has a 50 day moving average price of $13.16 and a two-hundred day moving average price of $14.69. The company has a market cap of $412.11 million and a PE ratio of -7.40. Nanobiotix has a 52 week low of $11.53 and a 52 week high of $21.55.
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. The company develops NanoXray products to help patients receiving radiotherapy by enhancing the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues.
Featured Story: The benefits and drawbacks of dollar cost averaging
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.